<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>342</serviceExecutionTime><Drug id="39832"><DrugName>SLV-311</DrugName><DrugSynonyms><Name><Value>SLV-311</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20199">Solvay SA</CompanyOriginator><CompaniesSecondary><Company id="20199">Solvay SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="39832" type="Drug"><TargetEntity id="320089" type="siDrug">SLV-311</TargetEntity></SourceEntity><SourceEntity id="20199" type="Company"><TargetEntity id="4298448939" type="organizationId">Solvay SA (Paris Branch)</TargetEntity></SourceEntity><SourceEntity id="461" type="Action"><TargetEntity id="731" type="Mechanism">Motilin Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01353" type="ciTarget"><TargetEntity id="104971939728623" type="siTarget">Motilin receptor</TargetEntity><TargetEntity id="2776" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="376">Gastric motility disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="461">Motilin receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="793">Gastroprokinetic</Action></ActionsSecondary><Technologies><Technology id="236">Macrolide</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A3F</Code><Name>GASTROPROKINETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-17T12:31:31.000Z</LastModificationDate><ChangeDateLast>2006-01-03T12:30:10.000Z</ChangeDateLast><AddedDate>2002-05-27T15:05:32.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20199" linkType="Company"&gt;Solvay&lt;/ulink&gt; was investigating SLV-311, a macrolide motilin agonist, for the potential treatment of gastric motility disorders [&lt;ulink linkID="451978" linkType="reference"&gt;451978&lt;/ulink&gt;], [&lt;ulink linkID="452823" linkType="reference"&gt;452823&lt;/ulink&gt;].  Preclinical work was underway in May 2002 [&lt;ulink linkID="454052" linkType="Reference"&gt;454052&lt;/ulink&gt;]; however, in December 2005, the company confirmed that development of SLV-311 had been discontinued [&lt;ulink linkID="643042" linkType="Reference"&gt;643042&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2002, preclinical data on SLV-311 were presented at the Digestive Disease Week meeting in San Francisco, CA. SLV-311 demonstrated higher affinity to motilin receptor from rabbit antrum smooth muscle cells (pIC50 = 8.01) than its analog erythromycin (pIC50 = 7.24). SLV-311 induced contractions in rabbit duodenum (pEC50 = 6.94 vs 5.95 for erythromycin). In conscious beagles administered 0.1 to 2.15 micromol/kg SLV-311 po, the drug dose-dependently inhibited olive oil-induced gastric relaxation (ED50 = 0.8 micromol/kg vs 5.3 micromol/kg for erythromycin), with complete inhibition at 2.16 micromol/kg. The olive oil-induced attenuation of duodenal motility was also inhibited (ED50 = 1.1 micromol/kg). These data suggested that SLV-311 treatment may be beneficial in stimulating gastric emptying, for example in diabetic gastroparesis [&lt;ulink linkID="452781" linkType="reference"&gt;452781&lt;/ulink&gt;], [&lt;ulink linkID="451978" linkType="reference"&gt;451978&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20199">Solvay SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="376">Gastric motility disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-12-23T00:00:00.000Z</StatusDate><Source id="643042" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="376">Gastric motility disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-05-22T00:00:00.000Z</StatusDate><Source id="451978" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="376">Gastric motility disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-11-22T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01353"><Name>Motilin receptor</Name><SwissprotNumbers><Swissprot>O43193</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>